Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04381689

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants

Phase Ⅲ, Randomized, Double-blind, Active Controlled to Evaluate the Immunogenicity and Safety of "IL-YANG Quadrivalent Seasonal Influenza Vaccine" in Healthy Infants From 6 Months to Under 3 Years of Age(≥ 6 Months and < 3 Years)

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
245 (estimated)
Sponsor
Il-Yang Pharm. Co., Ltd. · Industry
Sex
All
Age
6 Months – 3 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and \< 3 years)

Detailed description

The study is an Randomized, Double-blind, Active controlled Phase III study.

Conditions

Interventions

TypeNameDescription
BIOLOGICALIL-YANG FLU Vaccine Prefilled Syringe INJ.Teratect Prefilled Syringe Inj. 0.5mL
BIOLOGICALFluarix Tetra Pre-filled SyringeFluarix Tetra Pre-filled Syringe 0.5mL

Timeline

Start date
2024-10-23
Primary completion
2025-05-20
Completion
2026-05-31
First posted
2020-05-11
Last updated
2026-03-25

Locations

2 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04381689. Inclusion in this directory is not an endorsement.

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (NCT04381689) · Clinical Trials Directory